Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
22 authors.
Laura ErmellinoDivision of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-3378-1785
Riddhima BangaDivision of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Spiros GeorgakisInstitute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-9398-3143
Nicole P KadziochDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-0432-8658
Francesco ProcopioDivision of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Ana Alcaraz-SernaDivision of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-9452-6788
Oscar Alfageme-AbelloDivision of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-9963-7137
Raphaël PorretDivision of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0009-0007-2781-9250
Rebecca CecchinDivision of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0009-0007-8770-1940
Michail OrfanakisInstitute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0009-0009-7668-7439
Rachel SchellingDivision of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0001-6966-6626
Cloé BrennaInstitute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0009-0003-6267-0851
Duy-Cat CanBioinformatics Platform, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-6861-2893
Mathilde FoglieriniDivision of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0001-7538-4262
Oliver Y ChénBioinformatics Platform, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Laurent PerezDivision of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-8860-7928
Craig FenwickDivision of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-9435-0110
Matthieu PerreauDivision of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Constantinos PetrovasInstitute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-5067-5810
Roberto F SpeckDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-8453-1137
Giuseppe PantaleoDivision of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-3651-2721
Yannick D MullerDivision of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-0513-7156
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
The unique ability of chimeric antigen receptor (CAR) T cells to infiltrate tissues is revolutionizing our perspectives for tackling severe, refractory and otherwise untreatable diseases. In HIV, CAR-T cells have been designed to target viral biomarkers, with limited success so far. Here, we investigated the possibility of redirecting CAR-T cells against a cellular biomarker of the HIV reservoir, the programmed cell death protein 1 (PD-1). We designed two second-generation 4-1BB-CARs using the scFv of either a blocking (bPD1-CAR) or a nonblocking (nbPD1-CAR) anti-PD-1 monoclonal antibody. The CAR avidity modulated T cell sensitivity, trogocytosis, and effector functions, independently of the PD-1 signaling domain. Both anti-PD-1 CAR-T cells could persist for 70 days in HIV-infected humanized mice, correlating with viral protection and a disruption of the lymphoid architecture in the white pulp of the spleen. Together, our results open strategic avenues for reducing the HIV reservoir by demonstrating the feasibility of depleting specific T cell subpopulations.
Indexed as
HIV-1HIV InfectionsProgrammed Cell Death 1 ReceptorReceptors, Chimeric AntigenT-LymphocytesAnimalsHumansImmunotherapy, AdoptiveMiceProgrammed Cell Death 1 ReceptorReceptors, Chimeric Antigen
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.